Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

被引：3
|
作者：
Aguiar, Pedro, Jr. [1 ]
Perry, Luke A. [2 ]
Lopes, Gilberto L., Jr. [3 ]
机构：
[1] Univ Fed Sao Paulo, Oncol & Hematol Dept, Clin Oncol Sect, Sao Paulo, Brazil
[2] Monash Univ Sch Med, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
来源：
LUNG CANCER MANAGEMENT | 2016年 / 5卷 / 03期
关键词：
cost-effectiveness; health technology assessment; immunotherapy; lung cancer;
D O I：
10.2217/lmt-2016-0016
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：119 / 122
页数：4
相关论文
共 50 条
  • [11] Efficacy of Immune-Checkpoint Inhibitors and EGFR-TKIs in NSCLC Patients with High PD-L1 Expression
    Masuda, K.
    Horinouchi, H.
    Tanaka, M.
    Higashiyama, R.
    Shinno, Y.
    Sato, J.
    Yoshida, T.
    Matsumoto, Y.
    Goto, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S292 - S293
  • [12] Real-World Comparative Effectiveness in Advanced NSCLC and High PD-L1 with 1L Immune Checkpoint Inhibitors ± Chemotherapy
    Hsu, M. L.
    Xia, Q.
    Aggarwal, S.
    Nkhoma, E.
    R, D.
    Hager, T.
    Quek, R.
    Feliciano, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S598 - S598
  • [13] Identifying Resistance to Immune Checkpoint Inhibitors by Screening for PD-L1 and MHC I Expression on CTCs in Pts with NSCLC
    Leal, T.
    Schehr, J.
    Kamisnki, A.
    Campbell, T.
    Traynor, A.
    Lang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S924 - S925
  • [14] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [15] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors—combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Yimin Wang
    Hedong Han
    Fang Zhang
    Tangfeng Lv
    Ping Zhan
    Mingxiang Ye
    Yong Song
    Hongbing Liu
    British Journal of Cancer, 2022, 127 : 948 - 956
  • [16] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akinleye, Akintunde
    Rasool, Zoaib
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (01)
  • [17] Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye
    Zoaib Rasool
    Journal of Hematology & Oncology, 12
  • [18] PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?
    Al-Ahmadie, H.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1658 - 1659
  • [19] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
  • [20] Immune checkpoint inhibitors alone vs immune checkpoint inhibitors-combined chemotherapy for NSCLC patients with high PD-L1 expression: a network meta-analysis
    Wang, Yimin
    Han, Hedong
    Zhang, Fang
    Lv, Tangfeng
    Zhan, Ping
    Ye, Mingxiang
    Song, Yong
    Liu, Hongbing
    BRITISH JOURNAL OF CANCER, 2022, 127 (05) : 948 - 956
12345